What is WVE's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.71B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for WVE?

P/E (TTM) is n/a and 52-week range is $3.04 to $21.73 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s WVE figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for WVE?

The company profile lists revenue (TTM) near $68M, net income (TTM) near -$20.33B, EPS (TTM) near -$1.07 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Wave Life Sciences, Inc. based, and what identifiers does Chartloom list?

The company context section lists headquarters in Cambridge, Massachusetts, US, 197.2M shares outstanding, ISIN US94352A1043 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Wave Life Sciences, Inc.

$WVE

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Wave Life Sciences, Inc. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. The company is headquartered in Cambridge, Massachusetts and currently employs 317 full-time employees. The company went IPO on 2015-11-11. The firm's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNA interference (RNAi) (SpiNA) and RNA editing (AIMers), provides unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. The firm's pipeline is focused on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs and also includes clinical programs for Duchenne muscular dystrophy (DMD) and Huntington's disease, as well as several preclinical programs utilizing its versatile RNA medicines platform.

Employees

317

Website

wavelifesciences.com

IPO

2015-11-11

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US94352A1043

Headquarters

Cambridge, Massachusetts, US

Shares outstanding

197.2M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

85.50%

Browse other companiesFree AI scores and summaries for more stocks